Examkin

Soru

Zorluk: OrtaDiagnostic Workup and Test Sequencing

A 59-year-old male presents to the outpatient clinic reporting a three-week history of episodic right upper quadrant abdominal pain. The pain typically occurs following large meals, lasts for approximately an hour, and then resolves completely. He is currently asymptomatic. His vital signs are temperature 37.1°C (98.8°F), blood pressure 128/82 mmHg, heart rate 76/min, and respiratory rate 14/min. Physical examination reveals a soft, non-distended abdomen with mild deep palpation tenderness in the right upper quadrant, but no Murphy sign or peritoneal signs are present.

Laboratory studies are obtained and shown below:

Laboratory TestResultReference Range
Leukocyte count7,800/mm³4,500 - 11,000/mm³
Total bilirubin1.2 mg/dL0.1 - 1.2 mg/dL
Direct bilirubin0.4 mg/dL0.0 - 0.3 mg/dL
Aspartate aminotransferase (AST)95 U/L8 - 40 U/L
Alanine aminotransferase (ALT)110 U/L7 - 56 U/L
Alkaline phosphatase245 U/L44 - 147 U/L

An abdominal ultrasound demonstrates multiple echogenic foci with posterior acoustic shadowing in the gallbladder. The gallbladder wall is not thickened. The common bile duct measures 9 mm in diameter, but no obstructing calculus is directly visualized.

Which of the following is the most appropriate next step in the diagnostic evaluation of this patient?

  1. Magnetic resonance cholangiopancreatographyCevap
  2. B
    Endoscopic retrograde cholangiopancreatography
  3. C
    Computed tomography of the abdomen with intravenous contrast
  4. D
    Hepatobiliary iminodiacetic acid scintigraphy
  5. E
    Percutaneous transhepatic cholangiography

Cevap

Magnetic resonance cholangiopancreatography
This patient presents with biliary colic, elevated liver enzymes, and a dilated common bile duct on ultrasound. However, his total bilirubin is normal and there are no signs of ascending cholangitis. This clinical picture places him at intermediate risk for choledocholithiasis. According to current clinical guidelines, intermediate-risk patients should undergo further non-invasive evaluation to confirm the presence of a common bile duct stone before proceeding to invasive procedures. Magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound (EUS) are the most sensitive and specific non-invasive tests for this purpose. Proceeding with MRCP allows for definitive diagnosis without exposing the patient to the risks of an invasive procedure if no stone is present.

Adım Adım Çözüm

1
Stratify the patient's risk for choledocholithiasis based on clinical, laboratory, and sonographic findings.
The patient has a dilated common bile duct (9 mm) and elevated liver enzymes, but a normal bilirubin level and no signs of acute ascending cholangitis.
Risk stratification is essential to determine whether the patient proceeds to therapeutic intervention, further non-invasive imaging, or routine surgery.
2
Categorize the specific risk level using societal guidelines (e.g., ASGE criteria).
The patient falls into the intermediate-risk category.
Intermediate risk is defined by factors such as age over 55, a dilated common bile duct on ultrasound, or abnormal liver biochemistries without overt jaundice.
3
Select the appropriate diagnostic or therapeutic pathway for the intermediate-risk category.
Non-invasive confirmatory imaging with Magnetic resonance cholangiopancreatography (MRCP) or Endoscopic ultrasound (EUS) is indicated.
This approach avoids the significant procedural risks of an invasive therapeutic procedure unless a stone is definitively confirmed.

Anahtar Kavram

Patients at intermediate risk for choledocholithiasis (abnormal liver biochemistries, dilated common bile duct, age >55) should undergo non-invasive evaluation with MRCP or EUS prior to invasive therapeutic procedures.
Bu soruyu puanla

Konular

Diagnostic Workup and Test Sequencing

Bu konudan daha fazla soru